A novel binary adenovirus-based dual-regulated expression system for independent transcription control of two different transgenes

Journal of Gene Medicine

Volumn 7, Issue 12, 2005, Pages 1573-1585

  Gonzalez Nicolini, Valeria ^a   Fussenegger, Martin ^a  

^a ETH ZURICH   (Switzerland)

Author keywords

Adenovirus; CFP; p27Kip1; PIP system; Pristinamycin; SAMY; SEAP; Streptogramin; TET system; Tetracycline

Indexed keywords

ADENOVIRUS VECTOR; CYCLIN DEPENDENT KINASE INHIBITOR 1B; STREPTOGRAMIN; TETRACYCLINE;

ANIMAL CELL; ARTICLE; BIOTECHNOLOGY; CANCER CELL CULTURE; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CELL PROLIFERATION; CELL STRAIN BHK; CHO CELL; CONTROLLED STUDY; FIBROBLAST; GENE CONTROL; GENE EXPRESSION REGULATION; GENETIC ENGINEERING; GENETIC TRANSCRIPTION; GENETIC TRANSFECTION; GROWTH INHIBITION; HUMAN; HUMAN CELL; INTRACELLULAR SPACE; MAMMAL CELL; NONHUMAN; NUCLEIC ACID PROBE; PRIORITY JOURNAL; REPORTER GENE; TRANSGENE; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; VIRUS RECOMBINANT;

ADENOVIRIDAE; ANIMALS; CELL LINE; CHO CELLS; CRICETINAE; CRICETULUS; CYCLIN-DEPENDENT KINASE INHIBITOR P27; GENE EXPRESSION REGULATION; GENES, REPORTER; GENETIC VECTORS; HUMANS; STREPTOGRAMINS; TETRACYCLINE; TRANSFECTION; TRANSGENES;

ADENOVIRIDAE; ANIMALIA; CRICETINAE; CRICETULUS GRISEUS; MAMMALIA;

EID: 29744462590     PISSN: 1099498X     EISSN: 15212254     Source Type: Journal    
DOI: 10.1002/jgm.787     Document Type: Article

References (75)

1. Weber W, Fussenegger M. Approaches for trigger-inducible viral transgene regulation in gene-based tissue engineering. Curr Opin Biotechnol 2004; 15: 383-391.
2. Toniatti C, Bujard H, Cortese R, Ciliberto G. Gene therapy progress and prospects: transcription regulatory systems. Gene Ther 2004; 11: 649-657.
3. Gossen M, Bujard H. Tight control of gene expression in mammalian cells by tetracycline-responsive promoters. Proc Natl Acad Sci USA 1992; 89: 5547-5551.
4. Gossen M, Freundlieb S, Bender G, Muller G, Hillen W, Bujard H. Transcriptional activation by tetracyclines in mammalian cells. Science 1995; 268: 1766-1769.
5. Fussenegger M, Morris RP, Fux C, et al. Streptogramin-based gene regulation systems for mammalian cells. Nat Biotechnol 2000; 18: 1203-1208.
6. Weber W, Marty RR, Keller B, Rimann M, Kramer BP, Fussenegger M. Versatile macrolide-responsive mammalian expression vectors for multiregulated multigene metabolic engineering. Biotechnol Bioeng 2002; 80: 691-705.
7. Zhao HF, Boyd J, Jolicoeur N, Shen SH. A coumermycin/novo-biocin-regulated gene expression system. Hum Gene Ther 2003; 14: 1619-1629.
8. Rivera VM, Clackson T, Natesan S, et al. A humanized system for pharmacologic control of gene expression. Nat Med 1996; 2: 1028-1032.
9. Braselmann S, Graninger P, Busslinger M. A selective transcriptional induction system for mammalian cells based on Gal4-estrogen receptor fusion proteins. Proc Natl Acad Sci U S A 1993; 90: 1657-1661.
10. Beerli RR, Schopfer U, Dreier B, Barbas CF III. Chemically regulated zinc finger transcription factors. J Biol Chem 2000; 275: 32 617-32 627.
11. No D, Yao TP, Evans RM. Ecdysone-inducible gene expression in mammalian cells and transgenic mice. Proc Natl Acad Sci U S A 1996; 93: 3346-3351.
12. Boorsma M, Nieba L, Koller D, Bachmann MF, Bailey JE, Renner WA. A temperature-regulated replicon-based DNA expression system. Nat Biotechnol 2000; 18: 429-432.
13. Weber W, Marty RR, Link N, et al. Conditional human VEGF-mediated vascularization in chicken embryos using a novel temperature-inducible gene regulation (TIGR) system. Nucleic Acids Res 2003; 31: e69.
14. Weber W, Schoenmakers R, Spielmann M, et al. Streptomyces-derived quorum-sensing systems engineered for adjustable transgene expression in mammalian cells and mice. Nucleic Acids Res 2003; 31: e71.
15. Weber W, Malphettes L, de Jesus M, et al. Engineered Streptomyces quorum-sensing components enable inducible siRNA-mediated translation control in mammalian cells and adjustable transcription control in mice. J Gene Med 2005; in press.
16. Neddermann P, Gargioli C, Muraglia E, et al. A novel, inducible, eukaryotic gene expression system based on the quorum-sensing transcription factor TraR. EMBO Rep 2003; 4: 159-165.
17. Available: http://www.qbiogene.com/products/gene-expression/qmateslideshow/index.htm
18. Tascou S, Sorensen TK, Glenat V, et al. Stringent rosiglitazone-dependent gene switch in muscle cells without effect on myogenic differentiation. Mol Ther 2004; 9: 637-649.
19. Weber W, Rimann M, Spielmann M, et al. Gas-inducible transgene expression in mammalian cells and mice. Nat Biotechnol 2004; 22: 1440-1444.
20. Weber W, Fussenegger M. Inducible gene expression in mammalian cells and mice. Methods Mol Biol 2004; 267: 451-66.
21. Fussenegger M, Moser S, Mazur X, Bailey JE. Autoregulated multicistronic expression vectors provide one-step cloning of regulated product gene expression in mammalian cells. Biotechnol Prog 1997; 13: 733-740.
22. Fux C, Moser S, Schlatter S, Rimann M, Bailey JE, Fussenegger M. Streptogramin- and tetracycline-responsive dual regulated expression of p27(Kip1) sense and antisense enables positive and negative growth control of Chinese hamster ovary cells. Nucleic Acids Res 2001; 29: E19.
23. Kramer BP, Viretta AU, Daoud-El-Baba M, Aubel D, Weber W, Fussenegger M. An engineered epigenetic transgene switch in mammalian cells. Nat Biotechnol 2004; 22: 867-870.
24. Moser S, Rimann M, Fux C, Schlatter S, Bailey JE, Fussenegger M. Dual-regulated expression technology: a new era in the adjustment of heterologous gene expression in mammalian cells. J Gene Med 2001; 3: 529-49.
25. Edelstein ML, Abedi MR, Wixon J, Edelstein RM. Gene therapy clinical trials worldwide 1989-2004 - an overview. J Gene Med 2004; 6: 597-602.
26. Tomanin R, Scarpa M. Why do we need new gene therapy viral vectors? Characteristics, limitations and future perspectives of viral vector transduction. Curr Gene Ther 2004; 4: 357-372.
27. Vandendriessche TC. Clinical gene therapy - first international conference. IDrugs 2002; 5: 209-212.
28. Everts M, Curiel DT. Transductional targeting of adenoviral cancer gene therapy. Curr Gene Ther 2004; 4: 337-346.
29. Glasgow JN, Bauerschmitz GJ, Curiel DT, Hemminki A. Transductional and transcriptional targeting of adenovirus for clinical applications. Curr Gene Ther 2004; 4: 1-14.
30. Gomez-Manzano C, Yung WK, Alemany R, Fueyo J. Genetically modified adenoviruses against gliomas: from bench to bedside. Neurology 2004; 63: 418-426.
31. Liu M, Acres B, Balloul JM, et al. Gene-based vaccines and immunotherapeutics. Proc Natl Acad Sci USA 2004; 101: 14567-14571.
32. Kamen A, Henry O. Development and optimization of an adenovirus production process. J Gene Med 2004; 6: 184-192.
33. McConnell MJ, Imperiale MJ. Biology of adenovirus and its use as a vector for gene therapy. Hum Gene Ther 2004; 15: 1022-1033.
34. Trapnell BC. Quantitative evaluation of gene expression in freshly isolated human respiratory epithelial cells. Am J Physiol 1993; 264: 199-212.
35. Volpers C, Kochanek S. Adenoviral vectors for gene transfer and therapy. J Gene Med 2004; 6: 164-171.
36. Chen J, Bezdek T, Chang J, Kherzai AW, Willingham T, Azzara M, Nisen PD. A glial-specific, repressible, adenovirus vector for brain tumor gene therapy. Cancer Res 1998; 58: 3504-3507.
37. Harding TC, Geddes BJ, Murphy D, Knight D, Uney JB. Switching transgene expression in the brain using an adenoviral tetracycline-regulatable system. Nat Biotechnol 1998; 16: 553-555.
38. Massie B, Couture F, Lamoureux L, et al. Inducible overexpression of a toxic protein by an adenovirus vector with a tetracycline-regulatable expression cassette. J Virol 1998; 72: 2289-2296.
39. Molin M, Shoshan MC, Ohman-Forslund K, Linder S, Akusjarvi G. Two novel adenovirus vector systems permitting regulated protein expression in gene transfer experiments. J Virol 1998; 72: 8358-8361.
40. Neering SJ, Hardy SF, Minamoto D, Spratt SK, Jordan CT. Transduction of primitive human hematopoietic cells with recombinant adenovirus vectors. Blood 1996; 88: 1147-1155.
41. Yoshida Y, Hamada H. Adenovirus-mediated inducible gene expression through tetracycline-controllable transactivator with nuclear localization signal. Biochem Biophys Res Commun 1997; 230: 426-430.
42. Hu SX, Ji W, Zhou Y, Logothetis C, Xu HJ. Development of an adenovirus vector with tetracycline-regulatable human tumor necrosis factor alpha gene expression. Cancer Res 1997; 57: 3339-3343.
43. Nakagawa S, Massie B, Hawley RG. Tetracycline-regulatable adenovirus vectors: pharmacologic properties and clinical potential. Eur J Pharm Sci 2001; 13: 53-60.
44. Chellapan SP, Giordano A, Fischer PB. Role of cyclin-dependent kinases and their inhibitors in cellular differentiation and development. Curr Top Micro Immunol 1998; 227: 57-103.
45. Kamura T, Hara T, Matsumoto M, et al. Cytoplasmic ubiquitin ligase KPC regulates proteolysis of p27(Kip1) at G1 phase. Nat Cell Biol 2004; 6: 1229-1235.
46. Martinez LA, Chen Y, Fischer S, Conti C. Coordinated changes in cell cycle machinery occur during keratinocyte terminal differentiation. Oncogene 1999; 18: 397-406.
47. McArthur GA, Foley KP, Fero ML, et al. MAD1 and p27(KIP1) cooperate to promote terminal differentiation of granulocytes and to inhibit Myc expression and cyclin E-CDK2 activity. Mol Cell Biol 2002; 22: 3014-3023.
48. Rodier G, Makris C, Coulombe P, et al. p107 inhibits G1 to S phase progression by down-regulating expression of the F-box protein Skp2. J Cell Biol 2005; 168: 55-66.
49. Cho NH, Kim YT, Kim JW. Alteration of cell cycle in cervical tumor associated with human papillomavirus: cyclin-dependent kinase inhibitors. Yonsei Med J 2003; 43: 722-728.
50. Fero ML, Randel E, Gurley KE, Roberts JM, Kemp CJ. The murine gene p27Kip1 is haplo-insufficient for tumour suppression. Nature 1998; 396: 177-180.
51. Koguchi K, Nakatsuji Y, Nakayama K, Sakoda S. Modulation of astrocyte proliferation by cyclin-dependent kinase inhibitor p27(Kip1). Glia 2002; 37: 93-104.
52. Ophascharoensuk V, Fero ML, Hughes J, Roberts JM, Shankland SJ. The cyclin-dependent kinase inhibitor p27Kip1 safeguards against inflammatory injury. Nat Med 1998; 4: 575-580.
53. Vozza A, Borriello A, Criniti V, Vozza G, Della-Ragione F. New established melanoma cell lines: genetic and biochemical characterization of cell division cycle. J Eur Acad Dermatol Venereol 2003; 17: 37-41.
54. Yang C, Sun M, Ilic Z, Friedrich TD, Sell S. Reduced expression of p27kip1 and increased hepatocyte proliferation in p53-deficient mice. Mol Carcinog 2003; 36: 15-22.
55. Lowenheim H, Furness DN, Kil J, et al. Gene disruption of p27(Kip1) allows cell proliferation in the postnatal and adult organ of corti. Proc Natl Acad Sci U S A 1999; 96: 4084-4088.
56. Rivard N, Boucher MJ, Asselin C, L'Allemain G. MAP kinase cascade is required for p27 downregulation and S phase entry in fibroblasts and epithelial cells. Am J Physiol 1999; 277: 652-664.
57. Tanner FC, Yang ZY, Duckers E, Gordon D, Nabel GJ, Nabel EG. Expression of cyclin-dependent kinase inhibitors in vascular disease. Circ Res 1998; 82: 396-403.
58. Kip1) of cyclin-dependent kinase 4 activation. Cell 1994; 79: 487-496.
59. Kip1, a cyclin-dependent kinase I inhibitor and a potential mediator of extracellular antimitogenic signals. Cell 1994; 78: 59-66.
60. Ladha MH, Lee KY, Upton TM, Reed MF, Ewen ME. Regulation of exit from quiescence by p27 and cyclin D1-CDK4. Mol Cell Biol 1998; 18: 6605-6615.
61. Katner AL, Hoang QB, Gootam P, et al. Induction of cell cycle arrest and apoptosis in human prostate carcinoma cells by a recombinant adenovirus expressing p27(Kip1). Prostate 2002; 53: 77-87.
62. Li J, Yang XK, Yu XX, Ge ML, Wang WL, Zhang J, Hou YD. Overexpression of p27(KIP1) induced cell cycle arrest in G(1) phase and subsequent apoptosis in HCC-9204 cell line. World J Gastroenterol 2000; 6: 513-521.
63. Goukassian D, Diez-Juan A, Asahara T, et al. Overexpression of p27(Kip1) by doxycycline-regulated adenoviral vectors inhibits endothelial cell proliferation and migration and impairs angiogenesis. FASEB J 2001; 15: 1877-1885.
64. Fussenegger M, Schlatter S, Datwyler D, Mazur X, Bailey JE. Controlled proliferation by multigene metabolic engineering enhances the productivity of Chinese hamster ovary cells. Nat Biotechnol 1998; 16: 468-472.
65. Fussenegger M, Bailey JE. Molecular regulation of cell-cycle progression and apoptosis in mammalian cells: implications for biotechnology. Biotechnol Prog 1999; 146: 807-833.
66. Nyberg-Hoffman C, Shabram P, Li W, Giroux D, Aguilar-Cordova E. Sensitivity and reproducibility in adenoviral infectious titer determination. Nat Med 1997; 3: 808-811.
67. Dion LD, Fang J, Garver RI Jr. Supernatant rescue assay vs. polymerase chain reaction for detection of wild type adenovirus-contaminating recombinant adenovirus stocks. J Virol Methods 1996; 56: 99-107.
68. Berger J, Hauber J, Hauber R, Geiger R, Cullen BR. Secreted placental alkaline phosphatase: a powerful new quantitative indicator of gene expression in eukaryotic cells. Gene 1988; 66: 1-10.
69. Schlatter S, Rimann M, Kelm J, Fussenegger M. SAMY, a novel mammalian reporter gene derived from Bacillus stearothermophilus alpha-amylase. Gene 2002; 282: 19-31.
70. Fux C, Fussenegger M. Bidirectional expression units enable streptogramin-adjustable gene expression in mammalian cells. Biotechnol Bioeng 2003; 83: 618-25.
71. Fussenegger M. The impact of mammalian gene regulation concepts on functional genomic research, metabolic engineering, and advanced gene therapies. Biotechnol Prog 2001; 17: 1-51.
72. Cavazzana-Calvo M, Thrasher A, Mavilio F. The future of gene therapy. Nature 2004; 427: 779-781.
73. Corti O, Sabate O, Horellou P, et al. A single adenovirus vector mediates doxycycline-controlled expression of tyrosine hydroxylase in brain grafts of human neural progenitors. Nat Biotechnol 1999; 17: 349-354.
74. Fux C, Weber W, Daoud-El Baba M, Heinzen C, Aubel D, Fussenegger M. Novel macrolide-adjustable bidirectional expression modules for coordinated expression of two different transgenes in mice. J Gene Med 2003; 5: 1067-1079.
75. Addison CL, Hitt M, Kunsken D, Graham FL. Comparison of the human versus murine cytomegalovirus immediate early gene promoters for transgene expression by adenoviral vectors. J Gen Virol 1997; 78: 1653-1661.